Results 41 to 50 of about 2,191 (125)

Multi‐omics integration driving precision medicine in non‐small cell lung cancer: From molecular mechanisms to clinical translation

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
This review pivots from a conventional technology catalogue to a clinical‐problem‐oriented framework for non‐small cell lung cancer. By integrating spatial multi‐omics, metabolomics, and advanced artificial intelligence (e.g. Multi‐Omics Factor Analysis and Least Absolute Shrinkage and Selection Operator), we decode lipid metabolic reprogramming ...
Yuang Gao, Liyan Lin, Hongrui Zhou, Muchen Li, Yunye Mao, Xiangwei Ge, Yangyang Jia, Yupu Li, Shu Sheng, JinZhao Zhai, Boyu Qin, Jinliang Wang   +11 more
wiley   +1 more source

Precious Gene: The Application of RET-Altered Inhibitors

Molecules, 2022
The well-known proto-oncogene rearrangement during transfection (RET), also known as ret proto-oncogene Homo sapiens (human), is a rare gene that is involved in the physiological development of some organ systems and can activate various cancers, such as
Qitao Gou, Xiaochuan Gan, Longhao Li, Qiheng Gou, Tao Zhang   +4 more
doaj   +1 more source

From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju, HeeJae Choi, Shilpa Madari, Annie Carlisle, Ashish Sharma, Christina Kunz, Fenglei Huang   +6 more
wiley   +1 more source

Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET–mutant thyroid cancer

npj Precision Oncology
Genetic alternation of REarranged during Transfection (RET) that leads to constitutive RET activation is a crucial etiological factor for thyroid cancer.
Wenjing Chen, Sophie Dream, Pui-Yin Leung, Pui-Kei Wu, Stuart Wong, Jong-In Park   +5 more
doaj   +1 more source

Asymptomatic Medullary Thyroid Carcinoma With Isolated Carcinoembryonic Antigen Elevation in a Patient With Chronic Kidney Disease: A Case Report

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT Medullary thyroid carcinoma (MTC) is rare and typically presents with a palpable nodule. We report a 64‐year‐old asymptomatic woman with chronic kidney disease (CKD) diagnosed with MTC after incidental procalcitonin elevation on routine labs, highlighting procalcitonin as an atypical clue and the need to distinguish tumor‐related from CKD ...
Orhan Altınyüzük, Bartu Ediz, Serkan Feyyaz Yalın, Ergün Parmaksız   +3 more
wiley   +1 more source

Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system

Frontiers in Pharmacology
AimsThe objective of this study is to compare the adverse events (AEs) associated with pralsetinib and selpercatinib.MethodsTo evaluate the imbalance of AEs linked to pralsetinib and selpercatinib in real-world data, the reporting odds ratio (ROR) was ...
Qiong Jie, Yuanyuan Li, Li Jing, Jinjin Chen, Yang Li   +4 more
doaj   +1 more source

Early stage non–small cell lung cancer: Toward a risk‐adaptive paradigm in the era of biologic precision

CA: A Cancer Journal for Clinicians, Volume 76, Issue 5, September/October 2026.
Abstract The clinical landscape of early stage non–small cell lung cancer is at transformative crossroads. Driven by the widespread adoption of low‐dose computed tomography screening, the frequent detection of ground‐glass opacities, and a rising incidence among never‐smokers, the diagnostic center of gravity has shifted toward earlier, potentially ...
Chaoqi Zhang, Xuanyu Gu, Pan Wang, Dongyu Li, Guochao Zhang, Ting Wang, Peng Wu, Wei Rao, Shan Muhammad, Binghua Tan, Yun Che, Mobai Zhu, Qilin Qiao, Fanbo Lai, Bohui Zhao, Kailun Fei, Yue Wu, Zhihui Zhang, Min Dai, Wanqing Chen, Yawei Zhang, Nan Bi, Jie Wang, Jie He   +23 more
wiley   +1 more source

Advances in therapeutic approaches to gastric cancer

CA: A Cancer Journal for Clinicians, Volume 76, Issue 5, September/October 2026.
Abstract Gastric cancer remains a leading cause of cancer‐related mortality worldwide, with nearly 1 million new cases diagnosed annually. Despite innovations in diagnosis, most patients still present at advanced stages, contributing to a poor prognosis.
Feng Wang, Zi‐Xian Wang, Yu‐Jing Zhang, Ye He, Jia‐Fu Ji, Yuan‐Fang Li, Xiu‐Juan Qu, Yi Ba, Shu‐Qiang Yuan, Rui‐Hua Xu   +9 more
wiley   +1 more source

Case report: Eczematous adverse drug reaction after selpercatinib treatment

Frontiers in Oncology
This study reports a 50-year-old patient presented with eczematous drug-eruption induced by selpercatinib after the treatment of non-small cell lung cancer (NSCLC).
Bingrun Li, Peng Cao, Wenjing Xu, Litao Zhang   +3 more
doaj   +1 more source

Accelerating Pediatric Oncology Drug Development: Advances in Clinical Pharmacology, Trial Design, Non‐Clinical Evidence, and Regulatory Science

The Journal of Clinical Pharmacology, Volume 66, Issue 7, July 2026.
Abstract Pediatric oncology drug development remains uniquely challenging due to the rarity and biological heterogeneity of childhood cancers, ethical considerations in trial conduct, and the limited feasibility of large, randomized studies. Despite these barriers, recent years have seen a notable acceleration in the approval of oncology therapies for ...
Ya‐Feng Wen, Xiaoning Wang, Sarandeep Boyanapalli, Lee Anderson, Thao Dang, Guan Xing, Marianna Calvet, Tiffany Hart, Sreeneeranj Kasichayanula, Xiaochen Zhao   +9 more
wiley   +1 more source